The office of the national medical insurance administration and the general office of the National Health Commission issued the notice on improving the supporting measures for the centralized procurement and use of drugs (insulin special) organized by the state. The reporter learned on the 5th that the average price reduction of the drugs selected in the insulin project is 48%, which is expected to save a lot of medical insurance expenses. It is understood that the "group purchase" of the "national team" takes patients as the center, fully respects clinical choices, maintains the stability of clinical drug varieties and reduces the risk of substitution, and a variety of insulin are included in the scope of centralized collection. Among them, laiyoushi? And when? As the basic insulin of the original research, the average daily treatment cost has been reduced to less than 5 yuan, greatly improving the availability of "high-quality and affordable" drugs, which is great good news for a large number of diabetes patients in China. In fact, the treatment rate and compliance rate of diabetes in China are still at a low level, resulting in an increase in complications, which not only seriously affects the life and quality of life of patients, but also brings a heavy burden on national medical expenditure. Diabetes needs long-term management, which puts forward higher requirements for the effectiveness, safety and accessibility of drugs. Professor zhudalong, chairman of the diabetes branch of the Chinese Medical Association, introduced: "insulin, as an important drug for diabetes patients to control blood glucose, plays an irreplaceable role in achieving blood glucose standards. According to the Chinese guidelines for the prevention and treatment of type 2 diabetes (2020 Edition) , for patients with poor oral drug control, it is recommended to start basic insulin therapy. As a new generation of basic insulin, leyoushi? It can effectively help patients achieve stable glucose control and reduce the risk of hypoglycemia. It is more effective for elderly patients and patients with renal insufficiency. At the same time, its innovative mechanism and process improve the patient experience from the aspects of injection flexibility and comfort, and further improve the compliance. " Community, county and other grass-roots medical system is the first line of defense for chronic disease management. This time, the price of basic insulin in the original research has been greatly reduced, so that more grass-roots diabetes patients can use the world's advanced therapeutic drugs, which has become an important basis for standardized diabetes management. Insulin purchased in the name of "national team" will gradually reach patients in May. It is understood that patients can obtain drugs through hospitals, community pharmacies, Internet hospitals and other channels. (outlook new era)